Back to Search
SUSAN SLOVIN, MD
MD
Internal Medicine Physician
NPI: 1841261559IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
186296(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
JENNER MEDICAL COLLEGE
Class of 1990
Research & Publications (20)
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
PMID 17728713·Nat Clin Pract Oncol·2007
5-case
Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
PMID 18277959·Clin Adv Hematol Oncol·2007
6-review
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
PMID 17619878·Cancer Immunol Immunother·2007
3-trial
Emerging role of immunotherapy in the management of prostate cancer.
PMID 17447437·Oncology (Williston Park)·2007
6-review
Violaceous exanthem as a manifestation of metastatic prostate cancer in skin.
PMID 16461102·Urology·2006
5-case
Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?
PMID 16528286·Nat Clin Pract Urol·2006
6-review
Immunologic targeting: how to channel a minimal response for maximal outcome.
PMID 16679856·Curr Opin Urol·2006
6-review
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
PMID 15948673·Expert Opin Ther Targets·2005
6-review
A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
PMID 15837210·Vaccine·2005
8-other
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.
PMID 16361552·Clin Cancer Res·2005
8-other
Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto Rico.
PMID 16118688·IDrugs·2005
7-preclinical
Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.
PMID 16197613·Clin Prostate Cancer·2005
6-review
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
PMID 15726361·Cancer Immunol Immunother·2005
3-trial
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
PMID 14645418·J Clin Oncol·2003
4-observational
Biochemical relapse in prostate cancer: is PSA promoting stress and anxiety?
PMID 12466754·MedGenMed·2002
8-other
Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity.
PMID 11525292·Hematol Oncol Clin North Am·2001
6-review
Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?
PMID 18366293·Expert Rev Anticancer Ther·2008
6-review
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
PMID 19375217·Eur Urol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1841261559
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 36
- Publications
- 20
Are you this provider?
Claim Your Profile